Training the Next Generation of Cancer Scientists

National Cancer Institute training grant has supported UC San Diego scholars since 1984

The University of California, San Diego received a $2.5 million Institutional Ruth L. Kirschstein National Research Service Award from the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), to support four predoctoral and six postdoctoral scholars in the campus’s cancer training program. First awarded in 1984, the grant is the single longest-running NCI training grant at UC San Diego. The 2014 grant renewal will provide funding through 2019, when it will have completed 34 years of training for cancer investigators…. Read the full story from the UC San Diego Newsroom

More about the UC San Diego NIH/NCI Cancer Training Grant

Tumor Suppressor Mutations Alone Don’t Explain Deadly Cancer

Biomarker for head and neck cancers identified

Although mutations in a gene dubbed “the guardian of the genome” are widely recognized as being associated with more aggressive forms of cancer, researchers at the University of California, San Diego School of Medicine have found evidence suggesting that the deleterious health effects of the mutated gene may in large part be due to other genetic abnormalities, at least in squamous cell head and neck cancers. … Read the full story from the UCSD Newsroom


Trey Ideker, PhD

Trey Ideker, PhD, professor and chief in the Division of Medical Genetics and professor of bioengineering, is one of the study’s co-senior authors.

Other Department of Medicine faculty authors include Hannah Carter, PhD, assistant professor; and Scott M. Lippman, MD, professor of medicine and director of the UC San Diego Moores Cancer Center.

Hannah Carter, PhD Dr. Scott M. Lippman

UC San Diego-Human Longevity Inc. Agreement Seeks to Accelerate Medical Science

Thousands of patient genomes expected to fuel diverse medical research, beginning with cancer

The new collaborative research agreement between Human Longevity Inc. (HLI) and the University of California, San Diego, announced today, represents a significant and necessary step in efforts to research and translate the potential of the human genome into novel and real treatments and therapies able to change and improve the human condition.

“This agreement brings together the resources of two entities that, in combination, may ultimately help improve countless lives,” said David A. Brenner, MD, vice chancellor of health sciences at UC San Diego and dean of the UC San Diego School of Medicine. “HLI aims to bring leading-edge thinking in genomics technologies. UC San Diego boasts some of the world’s finest researchers and physicians working at places like the Moores Cancer Center. Together, we will collaborate to marshal the people, the tools and the resources to really make a difference in human health.” … Read the full story from the UC San Diego News Center

New Cancer Council Combines Local Centers’ Strengths

UC San Diego Moores Cancer Center, Salk Institute for Biological Studies and Sanford-Burnham Medical Research Institute come together in novel collaboration

San Diego is a powerhouse for cancer research, home to the University of California, San Diego Moores Cancer Center – the region’s only National Cancer Institute (NCI)-designated comprehensive cancer center – and two NCI-designated centers for basic research: the Salk Institute Cancer Center and the Cancer Center at Sanford-Burnham Medical Research Institute.

These singular enterprises have now formed a novel collaboration – the San Diego National Cancer Institute Cancer Centers Council, or C3 – to leverage their distinct and combined resources and talents. … Read the full story from the UCSD Newsroom


UC San Diego Moores Cancer Center

Dr. Scott Lippman Senior UC San Diego Moores Cancer Center leaders and Department of Medicine professors Scott Lippman, MD, and Barbara Parker, MD, are voting members of the new NCI Cancer Centers Council (C3).

Lippman is director and Chugai Pharmaceutical Chair, UC San Diego Moores Cancer Center and senior associate dean and assistant vice chancellor for Cancer Research and Care, UC San Diego.

Barbara A. Parker, MDParker is professor of clinical medicine, UCSD School of Medicine and deputy director for Clinical Affairs, UCSD Moores Cancer Center.

She received her internal medicine residency training, served as chief medical resident and did her hematology-oncology fellowship at UC San Diego.

Lippman is professor of medicine and Parker is professor of clinical medicine in the Division of Hematology-Oncology.

UC San Diego Moores Cancer Center Launches Bold Campaign to Personalize Cancer Treatment

“My Answer to Cancer” will analyze patient tumor DNA to individualize cancer care

UC San Diego Moores Cancer Center launched a bold plan today aimed at personalizing cancer treatment.  The “My Answer to Cancer” team of oncologists, bioinformaticians, pathologists and geneticists pledges to “sequence” or analyze the DNA of large numbers of patients with cancer in order to match each patient to the best available drug for his or her particular tumor. There will be two parallel approaches: a research approach to discover new mutations that cause cancer and a patient-care approach that will use confirmed mutations and other DNA abnormalities to direct patients to clinical studies of agents targeting these abnormalities. … Read the full story from the UC San Diego Newsroom.

More about the “My Answer to Cancer” Program:

Serving Up a Winning Strategy to Beat Cancer

News Feature from the UC San Diego Health System Newsroom

Serving Up a Winning Strategy to Beat Cancer
A profile of Dr. Scott M. Lippman

New director of Moores Cancer Center
by Kim Edwards

Scott M. Lippman, MD, new director of Moores Cancer Center is at the net, poised and ready to beat his fiercest opponent.

“In war, in any kind of battle, even a tennis match, you want to identify your opponent’s weakness and go after it,” said Lippman. “It’s the same with cancer. This is a war, and you want to have the strongest army and plan of attack.”… Read the full profile from the UC San Diego Health System newsroom